









108A peroxisome proliferator-activated receptor
gamma agonist attenuates neurological deﬁcits
following spinal cord ischemia in rats
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Objective: Neuroprotective effects of the peroxisome proliferator-activated receptor gamma (PPARg) agonist in cerebral
ischemia have been reported, but the effect of a PPARg agonist on spinal cord ischemia has not been investigated. The
objective of this study was to investigate the effect of a PPARg agonist on spinal cord ischemia. Pioglitazone, a PPARg
agonist, was administered in a rat model of spinal cord ischemia, and the extent of neurological damage and histological
alterations were assessed.
Methods: Forty-ﬁve rats were randomly enrolled into one of the three groups: (1) pioglitazone group (group PIO): rats
were treated with pioglitazone 24 hours before ischemia; (2) control group (group C): rats were treated with the same
volume of saline 24 hours before ischemia; and (3) sham group (group sham): rats were treated with the same volume of
saline 24 hours before the sham surgery. Spinal cord ischemia was induced using a balloon-tipped catheter placed on the
proximal descending aorta. Neurologic function was assessed using the motor deﬁcit index (0 [ normal, 6 [ complete
paralysis) during the 48 hours after reperfusion. Histological and biochemical evaluations were then performed.
Results: Compared with group C, group PIO presented with lower motor deﬁcit index 48 hours after reperfusion (5.0
[4.0-6.0] vs 3.0 [2.0-3.0]; group C vs group PIO, respectively; P < .001). Group PIO presented with a higher number
of normal motor neurons (10.7 [8.1-11.9] vs 14.7 [14.0-15.3]; group C vs group PIO, respectively; P [ .009) and
a smaller area of infarcts (48.4% [46.3%-54.0%] vs 16.8% [11.5%-18.3%]; group C vs group PIO, respectively; P[ .009)
when compared with group C. The degree of inﬂammatory reactions, assessed by microglia activities, was signiﬁcantly
reduced in group PIO. Oxidative stress level, assessed using malonydialdehyde assay, was signiﬁcantly reduced in group
PIO relative to group C (192.21% [173.5%-206.4%] of sham vs 141.1% [131.7%-152.1%] of sham; group C vs group
PIO, respectively; P [ .007). The sham group exhibited no abnormality upon neurological or histological examination.
Conclusions: PPARg agonist pioglitazone pretreatment signiﬁcantly reduces infarct volume and attenuates neurological
deﬁcits following spinal cord ischemia. The possible mechanism of neuroprotection by PPARg agonist may involve
modulation of inﬂammatory reaction and oxidative stress. (J Vasc Surg 2014;59:1084-9.)
Clinical Relevance: Spinal cord ischemia is a major issue in thoracoabdominal aortic surgery. The proliferator-activated
receptor agonists have been reported to exert protective effects on ischemia in various organs including cerebral ischemia.
This study investigated the effect of a proliferator-activated receptor gamma agonist pioglitazone on spinal cord ischemia
in a rat model of spinal cord ischemia. Our results present a protective effect of pioglitazone pretreatment to attenuate
spinal cord ischemic injury. Considering that pioglitazone is currently a U.S. Food and Drug Administration-approved
agent for treatment of type 2 diabetes, it may be applied in clinical practice to attenuate spinal cord ischemia injury
following thoracoabdominal aortic surgery.Postoperative neurological deﬁcit secondary to spinal hypothermia, are currently adopted in clinical practice to
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(PPARs) are expressed in a broad range of tissues and regu-
late cellular metabolism and homeostasis.5 Recently,
PPARg agonists have been reported to exert protective
effects on ischemia in various organs including peripheral
nerves,6 brain,7-14 liver,15 and heart.16 The related mecha-
nisms are thought to be modulation of inﬂammatory reac-
tion7,9-11,13,16 and modulation of oxidative stress.6,11,12,15
To date, the protective effect of PPARg agonists on spinal
cord ischemia has not been investigated. In central nervous
system (CNS) injury models, such as ischemic stroke or
Parkinson’s disease, PPARg agonists offer a neuroprotective
effect through modulation of inﬂammation or reduction
of oxidative stress.7,9-12 Since both the inﬂammatory reac-
tion1,17-19 and oxidative stress4,20 play important roles
in spinal cord ischemia, we hypothesized that PPARg
agonists could exert a protective effect against spinal cord
ischemia.
Pioglitazone, a potent synthetic PPARg agonist, has
been reported to exert protective effects in various organ
ischemic injuries.6-9,11-13,15,16 To investigate the effect of
a PPARg agonist on spinal cord ischemia, we administered
pioglitazone to a rat model of spinal cord ischemia. The
extent of neurological injury and histopathological changes
were compared with rats treated with vehicle only.
METHODS
General animal care and experimental protocol.
This study protocol was approved by the Institutional
Animal Care and Use Committee of Seoul National Univer-
sity Bundang Hospital. Animal care and all procedures were
performed according to the U.S. National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
Male Sprague-Dawley rats weighing 270 to 330 g were
used. Animals with any neurological abnormality were not
used in this experiment. Rats were randomly enrolled into
one of the three following groups. Pioglitazone group
(group PIO, n ¼ 15): 24 hours before spinal cord ischemia,
animals received 20 mg/kg pioglitazone (Actos; Takeda
Pharmaceutical Company Limited, Osaka, Japan) orally.
The dose and admission timing were decided based on
the previous studies.8,12,15 Control group (group C, n ¼
15): animals received saline orally 24 hours before spinal
cord ischemia, and the sham group (group sham, n ¼
15): animals received saline orally 24 hours before sham
surgery. After the last neurological assessment, the animals
in each group were divided into three subgroups; for histo-
logical assessment (n ¼ 5), for infarct volume assessment
(n ¼ 5), and for oxidative stress assessment (n ¼ 5).
Induction of spinal cord ischemia. General anes-
thesia was induced by placing the animals in a plastic
chamber ﬁlled with 3.0 to 4.0 vol% isoﬂurane and was
maintained by applying a face mask connected to
a gaseous anesthesia system with 1.5 to 2.0 vol% isoﬂur-
ane. Spinal cord ischemia was induced by placement of
a balloon-tipped catheter in the thoracic aorta as
described previously.2 In brief, after surgical incision,
a balloon-tipped catheter (Fogarty Arterial EmbolectomyCatheter; Edward Life Sciences, Irvine, Calif) was inser-
ted into the femoral artery and advanced into the
descending thoracic aorta. The right carotid artery was
exposed and cannulated with a 20-gauge intravenous
catheter, which was connected to an external blood
reservoir. The tail artery was cannulated with a poly-
ethylene catheter to monitor distal arterial blood pres-
sure. After administration of 150 U of heparin, the
Fogarty catheter was inﬂated with 0.05 mL of saline. At
the same time, blood was allowed to drain through the
carotid cannula into the external blood reservoir to
prevent proximal hypertension. Aortic occlusion was
conﬁrmed by a sudden and complete loss of the distal
arterial pressure monitored at the tail artery. After 11
minutes of aortic occlusion, the balloon was deﬂated, and
the blood in the reservoir was reinfused into the rat. After
removal of catheters and wound closure, the animals were
allowed to recover and were returned to their cages. To
check the effect of pioglitazone on serum glucose levels in
each group, the serum glucose levels were measured in
each animal. They were measured immediately before the
aortic occlusion and 10 minutes after reperfusion.
Assessment of hind limb motor function. The
neurologic function was assessed at 8, 24, and 48 hours after
reperfusion by an observer blinded to the study protocol.
Hind limb motor function was evaluated using the motor
deﬁcit index (MDI),21 which is the sum of ambulation
score and the placing and stepping score. Ambulation was
graded as follows: 0, normal (symmetrical and coordinated
ambulation); 1, toes ﬂat under body when walking, but
ataxia present; 2, knuckle-walking; 3, movement in lower
extremities but unable to knuckle-walk; and 4, no move-
ment, drags lower extremities. The placing and stepping
reﬂex was assessed by dragging the dorsum of the hind paw
over the edge of a surface. Normally, this evokes a coordi-
nating lifting and placing (stepping) response. Placing and
stepping reﬂex was graded as follows: 0, normal; 1, weak;
and 2, no stepping. The MDI was evaluated by a researcher
who was blinded to the group assignment.
Histology and immunohistochemistry. After the last
neurological assessment, ﬁve rats from each group were
euthanized, and spinal cord segments at the levels of L3-5
were embedded in parafﬁn. Transverse sections were cut
and stained with hematoxylin and eosin. An investigator
blinded to the group assignment counted the number of
motor neurons in Rexed’s laminae VII, VIII, and IX.
Immunohistochemical staining for ionized calcium-binding
adaptor molecule 1 (Iba-1), a microglia-speciﬁc antibody,22
was also performed. Endogenous peroxidase activity was
quenched by incubatingwith 0.3%H2O2. After a 60-minute
incubation with blocking buffer, sections were incubated
overnight at 4C with an Iba-1 antibody (Iba1, 1:300;
Wako, Osaka, Japan) containing 0.3% Triton X-100. After
washing with phosphate-based buffer, immunoperoxidase
histochemistry was performed by the Avidin-Biotin
Complex method (Vectastain ABC System; Vector Labo-
ratories, Burlingame, Calif). A blinded investigator counted
the number of activated microglia in four randomly selected
Fig 1. Motor deﬁcit index (MDI). Group C, Animals received
normal saline before ischemia; group pioglitazone (PIO), animals
received pioglitazone before ischemia; group Sham, animals received
saline before sham surgery. MDImeasured 8 (a), 24 (b), and 48 (c)
hours postreperfusion. At each time point, MDI was signiﬁcantly
different among the groups (P< .0001, each); group PIO exhibited
signiﬁcantly lower MDI than group C (P < .001, at each time
point). Group Sham showed no neurological abnormality.
Fig 2. Number of normal motor neurons. Data are expressed as
medians with interquartile ranges. Group C, animals received
normal saline before ischemia; group pioglitazone (PIO), animals
received pioglitazone before ischemia; group Sham, animals
received saline before sham surgery. The number of normal motor
neurons was signiﬁcantly different among the groups (P ¼ .0019).
Groups PIO and C exhibited a lower number of motor neurons
compared with group Sham (P ¼ .0090, each). Group PIO
exhibited a signiﬁcantly greater number of motor neurons
compared with group C (P ¼ .0090).
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cell counter function of Image J (National Institutes of
Health, Bethesda, Md). Activated microglia were identiﬁed
by dense Iba-1 immunolabeling and identiﬁcation of distinct
morphological characteristics of thickened and retracted
process or an ameboid-like appearance.23,24Measurement of infarct area. Infarct volume assess-
ment was performed by 2,3,5-triphenyltetrazolin chloride
staining. Five rats from each group were perfused trans-
cardially with 37C 0.4% 2,3,5-triphenyltetrazolin chloride.
After 30 minutes of incubation, the spinal cord was
removed and ﬁxed with 10% formalin. Spinal cord segments
at the levels of L3-5 were cut into 3-mm coronal sections.
The normal area of spinal cord was stained bright red
based on intact mitochondrial function, whereas the infarct
area remained unstained.25 Each slice was photographed,
and the infarct area was measured using Image J.
Assessment of oxidative stress. Oxidative stress was
assessed by the lipid peroxidation end product malonydial-
dehyde (MDA). Five rats from each group were perfused
transcardially with ice-cold saline, and spinal cord tissue
was extracted. Levels of MDA were measured according to
the manufacturer’s protocol (MDA-586; OxisResearch,
Percipio Biosciences, Burlingame, Calif).26 Brieﬂy, the
spinal cord was homogenized in phosphate-buffered saline
with a weight-to-volume ratio of 1:10. The homogenate
was centrifuged at 3000 rpm for 10 minutes. Aliquots of
supernatant were treated with N-methyl-2-phenylindole at
45C for 60 minutes and centrifuged. The absorbance at
586 nm was then recorded.
Statistical analysis. Between-group comparisons were
performed using Kruskal-Wallis test. The Mann-WhitneyU
test was subsequently used when necessary. The changes in
serum glucose level within each group were compared
using the Wilcoxon test. A P value of less than .05 was
considered to indicate statistical signiﬁcance. Data were
expressed as medians (interquartile range).
Fig 3. Ionized calcium-binding adaptor molecule 1 (iba-1) immunohistochemistry. a, Number of activated microglia
was signiﬁcantly different among the groups (P ¼ .0018). Group pioglitazone (PIO) showed a signiﬁcantly lower
number of activated microglia than group C (P ¼ .0090). Group sham exhibited very few activated microglia. Data are
expressed as medians with interquartile ranges. b, Representative photographs of each group (magniﬁcation, 200). b-
1, Group C presented dense iba-1 immunostaining. A large number of highly activated microglia, characterized by
dense thick processes or ameboid shapes is evident; b-2, Group PIO. Compared with group C, group PIO presented
with fewer activated microglia and morphologic features of a less-activated form; b-3, Group sham showed fewer
microglia, which were mostly in a ramiﬁed or quiescent form.
Fig 4. Spinal cord tissue malonydialdehyde (MDA) level. MDA
levels differed among the three groups (P ¼ .0015). Group piogli-
tazone (PIO) showed a signiﬁcantly reduced MDA level compared
with group C (P ¼ .0090). However, the MDA level of group PIO
was signiﬁcantly higher than that of group sham (P ¼.0071). Data
are expressed as medians with interquartile ranges.
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The results of the neurological assessment are pre-
sented in Fig 1. At 8 hours postreperfusion, the group
PIO exhibited signiﬁcantly lower MDI than group C;
this trend was sustained throughout the study period.
The sham group did not present any neurological abnor-
malities throughout the study period.
The number of viable motor neurons is presented in
Fig 2. The number of viable neurons was signiﬁcantly higher
in group PIO than group C.However, when compared with
group sham, group PIO had a signiﬁcantly lower number of
viable neurons. The infarct volume was signiﬁcantly reduced
in group PIOwhen compared with group C (48.4% [46.2%-
54.0%] vs 16.8% [11.5%-18.3%]; group C vs group PIO,
respectively; P ¼ .009). Group sham had no infarcts.
Group C exhibited an increased number of activated
microglia compared with group PIO or the sham group
(Fig 3). Group C showed abundant activated microglia,
which are characterized by strong immunostaining, short,
thickened processes, or ameboid shapes. Group PIO had
a decreased number of activated microglia compared with
group C. Group sham had very weak Iba-1 immunoreac-
tivity, which were in a ramiﬁed or quiescent form.
The result of MDA assay is presented in Fig 4. MDA
levels in the spinal cord tissue were signiﬁcantly higher in
group C and group PIO compared with the sham group.Pioglitazone treatment signiﬁcantly reduced the MDA
level, but not to the level in the sham animals.
Intraoperative serum glucose levels are shown in the
Table. During the preocclusion period, there was no
Table. Serum glucose level
Group C Group PIO Group Sham
Preocclusion 96.0 (93.3-112.5) 102.0 (96.5-117.0) 98.0 (89.3-108.0)
Postreperfusion 132.0 (121.0-190.3)a,b 145.0 (129.8-187.0)a,b 99.0 (91.3-103.0)
Group C, Animals received normal saline before ischemia; Group PIO, animals received pioglitazone before ischemia; Group Sham, animals received saline
before sham surgery; PIO, pioglitazone.
Values are median (interquartile range); Preocclusion serum glucose levels were not different among the groups. Postreperfusion serum glucose levels were
signiﬁcantly different among the groups. In groups C and PIO, postreperfusion serum glucose levels were signiﬁcantly higher than that in group sham, with no
difference between the group C and group PIO. In the sham group, pre- and postreperfusion serum glucose were not different. In groups C and PIO,
postreperfusion serum glucose levels were signiﬁcantly higher than preocclusion values; no difference was found between the groups.
aP < .001, preocclusion vs postreperfusion, within each group.
bP < .001 vs group sham.
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reperfusion blood glucose values were signiﬁcantly
increased in group C and group PIO; differences between
the groups were not signiﬁcant.
DISCUSSION
Our results showed that pioglitazone reduced infarct
volume and attenuated neurological deﬁcits following
spinal cord ischemia. To our knowledge, this is the ﬁrst
investigation of the neuroprotective effect of a PPARg
agonist against spinal cord ischemia.
The PRARs exist as three different isoforms of
PPARa, PPAR b/d, and PPARg.5 Of these, PPARg
agonists have anti-inﬂammatory7,9-11,13,16,27-29 and anti-
oxidative6,11,12,15 effects and protect various organs from
ischemic injury.6-13,15,16 In the CNS, PPARg agonist offers
neuroprotective effects not only in ischemic injury,7-13 but
also other types of cerebral pathology such as Alzheimer’s
disease,27 Parkinson’s disease,28 and trauma.29-31
Our data, which demonstrate the neuroprotective effect
of pioglitazone against spinal cord ischemia, are in agreement
with previous reports using cerebral ischemia models. In
a transient7,9,10,12,13 or permanent8 cerebral ischemiamodel,
PPARg agonists reduced infarct volume and improved
neurological outcome though its anti-inﬂammatory effects
or antioxidative effects. Our data are in agreement with
previous reports of cerebral ischemia, in which group PIO
presented a lower MDI score and a reduced infarct volume,
demonstrating that PPARg agonists exert neuroprotective
effects against spinal cord ischemia.
Although there has been no report of the effect of
PPARg agonists on spinal cord ischemia, its role in trau-
matic spinal cord injury has been reported. In a rat model
of traumatic spinal cord injury, the PPARg agoinsts piogli-
tazone and rosiglitazone were reported to reduce motor
neuron loss and improve the neurological outcome.30,31
Our results are somewhat consistent with the results from
the traumatic spinal cord ischemia model.
In our study, groupPIOexhibited signiﬁcantly attenuated
microglial activation. Microglia, the resident macrophages of
the CNS, rapidly transform into an activated state in response
to various CNS insults, modulating inﬂammatory processes
and playing important roles in cerebral or spinal cord ischemic
injury.19,24,32-34 PPARg agonists effectively attenuatemicroglial activation in various types of CNS injury, including
cerebral ischemia,9,13 traumatic brain injury,29 traumatic spinal
cord injury,30 and Parkinson’s disease.28 Our results that
suggest that PPARg agonists actively attenuate the activation
of microglia is compatible with previous reports, and suggest
that the neuroprotective effects of PPARg agonists against
spinal cord injury are related to its anti-inﬂammatory effect,
including attenuation of microglial activation.
CNS injury increases oxygen-free radicals,whichmediate
secondary neuronal damage. Several studies have reported
the antioxidative effects of PPARg agonists. PPARg agonists
have been reported to induce antioxidative enzymes11,30 and
reduce oxidative metabolites11,12 after ischemic stroke11,12
and traumatic spinal cord injury.30 MDA is the ﬁnal product
of lipid peroxidation, and its level reﬂects free-radical levels.
Our data show that MDA levels in group PIO decreased
signiﬁcantly compared with group C. Therefore, our data
suggest that the antioxidative effectsmaybeoneof theunder-
lying mechanisms of PPARg agonist-induced neuroprotec-
tion in spinal cord ischemia.
Although pioglitazone is clinically used as an antidiabetic
medication, group PIO and group C exhibited no difference
in serum glucose levels during the surgery. Although thiazo-
lidinediones increase insulin sensitization in patients with
type 2 diabetes,5 they do not affect blood glucose level in
nondiabetic patients.35 Our data also suggest that themech-
anism of the neuroprotective effects of pioglitazone in spinal
cord ischemia does not depend on its anti-hyperglycemic
effect. This result is in alignment with previous ﬁndings in
cerebral ischemia,8,13 which showed that the neuroprotec-
tive effect of PPARg agonists against ischemic stroke is unre-
lated to its antihyperglycemic action.
CONCLUSIONS
The PPARg agonist pioglitazone improves neurolog-
ical outcome following spinal cord ischemia in rats. It
improves motor neuron survival and reduces infarct
volume. The possible mechanisms for these ﬁndings are
the anti-inﬂammatory and antioxidative effects of PPARg
agonists. Considering that pioglitazone is safely prescribed
in patients with diabetes, our result suggests the possibility
of pioglitazone as a clinically applicable pharmacologic neu-
roprotective strategy in patients undergoing thoracoabdo-
minal aortic surgery.
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